Standard

Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. / Zecha, Judith A. E. M.; Raber-Durlacher, Judith E.; Nair, Raj G. et al.

In: Supportive care in cancer, Vol. 24, No. 6, 2016, p. 2781-2792.

Research output: Contribution to journalReview articleAcademicpeer-review

Harvard

Zecha, JAEM, Raber-Durlacher, JE, Nair, RG, Epstein, JB, Sonis, ST, Elad, S, Hamblin, MR, Barasch, A, Migliorati, CA, Milstein, DMJ, Genot, M-T, Lansaat, L, van der Brink, R, Arnabat-Dominguez, J, van der Molen, L, Jacobi, I, van Diessen, J, de Lange, J, Smeele, LE, Schubert, MM & Bensadoun, R-J 2016, 'Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations', Supportive care in cancer, vol. 24, no. 6, pp. 2781-2792. https://doi.org/10.1007/s00520-016-3152-z

APA

Zecha, J. A. E. M., Raber-Durlacher, J. E., Nair, R. G., Epstein, J. B., Sonis, S. T., Elad, S., Hamblin, M. R., Barasch, A., Migliorati, C. A., Milstein, D. M. J., Genot, M-T., Lansaat, L., van der Brink, R., Arnabat-Dominguez, J., van der Molen, L., Jacobi, I., van Diessen, J., de Lange, J., Smeele, L. E., ... Bensadoun, R-J. (2016). Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. Supportive care in cancer, 24(6), 2781-2792. https://doi.org/10.1007/s00520-016-3152-z

Vancouver

Author

BibTeX

@article{84b59a17a15949d0ab83f7558fbacbfe,
title = "Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations",
abstract = "There is a large body of evidence supporting the efficacy of low level laser therapy (LLLT), more recently termed photobiomodulation (PBM), for the management of oral mucositis (OM) in patients undergoing radiotherapy for head and neck cancer (HNC). Recent advances in PBM technology, together with a better understanding of mechanisms involved, may expand the applications for PBM in the management of other complications associated with HNC treatment. This article (part 1) describes PBM mechanisms of action, dosimetry, and safety aspects and, in doing so, provides a basis for a companion paper (part 2) which describes the potential breadth of potential applications of PBM in the management of side-effects of (chemo)radiation therapy in patients being treated for HNC and proposes PBM parameters. This study is a narrative non-systematic review. We review PBM mechanisms of action and dosimetric considerations. Virtually, all conditions modulated by PBM (e.g., ulceration, inflammation, lymphedema, pain, fibrosis, neurological and muscular injury) are thought to be involved in the pathogenesis of (chemo)radiation therapy-induced complications in patients treated for HNC. The impact of PBM on tumor behavior and tumor response to treatment has been insufficiently studied. In vitro studies assessing the effect of PBM on tumor cells report conflicting results, perhaps attributable to inconsistencies of PBM power and dose. Nonetheless, the biological bases for the broad clinical activities ascribed to PBM have also been noted to be similar to those activities and pathways associated with negative tumor behaviors and impeded response to treatment. While there are no anecdotal descriptions of poor tumor outcomes in patients treated with PBM, confirming its neutrality with respect to cancer responsiveness is a critical priority. Based on its therapeutic effects, PBM may have utility in a broad range of oral, oropharyngeal, facial, and neck complications of HNC treatment. Although evidence suggests that PBM using LLLT is safe in HNC patients, more research is imperative and vigilance remains warranted to detect any potential adverse effects of PBM on cancer treatment outcomes and survival",
author = "Zecha, {Judith A. E. M.} and Raber-Durlacher, {Judith E.} and Nair, {Raj G.} and Epstein, {Joel B.} and Sonis, {Stephen T.} and Sharon Elad and Hamblin, {Michael R.} and Andrei Barasch and Migliorati, {Cesar A.} and Milstein, {Dan M. J.} and Marie-Th{\'e}r{\`e}se Genot and Liset Lansaat and {van der Brink}, Ron and Josep Arnabat-Dominguez and {van der Molen}, Lisette and Irene Jacobi and {van Diessen}, Judi and {de Lange}, Jan and Smeele, {Ludi E.} and Schubert, {Mark M.} and Ren{\'e}-Jean Bensadoun",
year = "2016",
doi = "10.1007/s00520-016-3152-z",
language = "English",
volume = "24",
pages = "2781--2792",
journal = "Supportive care in cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "6",

}

RIS

TY - JOUR

T1 - Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations

AU - Zecha, Judith A. E. M.

AU - Raber-Durlacher, Judith E.

AU - Nair, Raj G.

AU - Epstein, Joel B.

AU - Sonis, Stephen T.

AU - Elad, Sharon

AU - Hamblin, Michael R.

AU - Barasch, Andrei

AU - Migliorati, Cesar A.

AU - Milstein, Dan M. J.

AU - Genot, Marie-Thérèse

AU - Lansaat, Liset

AU - van der Brink, Ron

AU - Arnabat-Dominguez, Josep

AU - van der Molen, Lisette

AU - Jacobi, Irene

AU - van Diessen, Judi

AU - de Lange, Jan

AU - Smeele, Ludi E.

AU - Schubert, Mark M.

AU - Bensadoun, René-Jean

PY - 2016

Y1 - 2016

N2 - There is a large body of evidence supporting the efficacy of low level laser therapy (LLLT), more recently termed photobiomodulation (PBM), for the management of oral mucositis (OM) in patients undergoing radiotherapy for head and neck cancer (HNC). Recent advances in PBM technology, together with a better understanding of mechanisms involved, may expand the applications for PBM in the management of other complications associated with HNC treatment. This article (part 1) describes PBM mechanisms of action, dosimetry, and safety aspects and, in doing so, provides a basis for a companion paper (part 2) which describes the potential breadth of potential applications of PBM in the management of side-effects of (chemo)radiation therapy in patients being treated for HNC and proposes PBM parameters. This study is a narrative non-systematic review. We review PBM mechanisms of action and dosimetric considerations. Virtually, all conditions modulated by PBM (e.g., ulceration, inflammation, lymphedema, pain, fibrosis, neurological and muscular injury) are thought to be involved in the pathogenesis of (chemo)radiation therapy-induced complications in patients treated for HNC. The impact of PBM on tumor behavior and tumor response to treatment has been insufficiently studied. In vitro studies assessing the effect of PBM on tumor cells report conflicting results, perhaps attributable to inconsistencies of PBM power and dose. Nonetheless, the biological bases for the broad clinical activities ascribed to PBM have also been noted to be similar to those activities and pathways associated with negative tumor behaviors and impeded response to treatment. While there are no anecdotal descriptions of poor tumor outcomes in patients treated with PBM, confirming its neutrality with respect to cancer responsiveness is a critical priority. Based on its therapeutic effects, PBM may have utility in a broad range of oral, oropharyngeal, facial, and neck complications of HNC treatment. Although evidence suggests that PBM using LLLT is safe in HNC patients, more research is imperative and vigilance remains warranted to detect any potential adverse effects of PBM on cancer treatment outcomes and survival

AB - There is a large body of evidence supporting the efficacy of low level laser therapy (LLLT), more recently termed photobiomodulation (PBM), for the management of oral mucositis (OM) in patients undergoing radiotherapy for head and neck cancer (HNC). Recent advances in PBM technology, together with a better understanding of mechanisms involved, may expand the applications for PBM in the management of other complications associated with HNC treatment. This article (part 1) describes PBM mechanisms of action, dosimetry, and safety aspects and, in doing so, provides a basis for a companion paper (part 2) which describes the potential breadth of potential applications of PBM in the management of side-effects of (chemo)radiation therapy in patients being treated for HNC and proposes PBM parameters. This study is a narrative non-systematic review. We review PBM mechanisms of action and dosimetric considerations. Virtually, all conditions modulated by PBM (e.g., ulceration, inflammation, lymphedema, pain, fibrosis, neurological and muscular injury) are thought to be involved in the pathogenesis of (chemo)radiation therapy-induced complications in patients treated for HNC. The impact of PBM on tumor behavior and tumor response to treatment has been insufficiently studied. In vitro studies assessing the effect of PBM on tumor cells report conflicting results, perhaps attributable to inconsistencies of PBM power and dose. Nonetheless, the biological bases for the broad clinical activities ascribed to PBM have also been noted to be similar to those activities and pathways associated with negative tumor behaviors and impeded response to treatment. While there are no anecdotal descriptions of poor tumor outcomes in patients treated with PBM, confirming its neutrality with respect to cancer responsiveness is a critical priority. Based on its therapeutic effects, PBM may have utility in a broad range of oral, oropharyngeal, facial, and neck complications of HNC treatment. Although evidence suggests that PBM using LLLT is safe in HNC patients, more research is imperative and vigilance remains warranted to detect any potential adverse effects of PBM on cancer treatment outcomes and survival

U2 - 10.1007/s00520-016-3152-z

DO - 10.1007/s00520-016-3152-z

M3 - Review article

C2 - 26984240

VL - 24

SP - 2781

EP - 2792

JO - Supportive care in cancer

JF - Supportive care in cancer

SN - 0941-4355

IS - 6

ER -

ID: 2882109